SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018298
Filing Date
2023-11-08
Accepted
2023-11-08 16:45:28
Documents
60
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q anvs-20230930x10q.htm   iXBRL 10-Q 1114701
2 EX-31.1 anvs-20230930xex31d1.htm EX-31.1 13515
3 EX-31.2 anvs-20230930xex31d2.htm EX-31.2 13552
4 EX-32.1 anvs-20230930xex32d1.htm EX-32.1 5714
5 EX-32.2 anvs-20230930xex32d2.htm EX-32.2 5703
  Complete submission text file 0001558370-23-018298.txt   5238625

Data Files

Seq Description Document Type Size
6 EX-101.SCH anvs-20230930.xsd EX-101.SCH 32808
7 EX-101.CAL anvs-20230930_cal.xml EX-101.CAL 21846
8 EX-101.DEF anvs-20230930_def.xml EX-101.DEF 132368
9 EX-101.LAB anvs-20230930_lab.xml EX-101.LAB 275911
10 EX-101.PRE anvs-20230930_pre.xml EX-101.PRE 232373
54 EXTRACTED XBRL INSTANCE DOCUMENT anvs-20230930x10q_htm.xml XML 987025
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

IRS No.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39202 | Film No.: 231388876
SIC: 2834 Pharmaceutical Preparations